AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Evogene Ltd.

$0.49 -$0.64 (-56.21%)
NASDAQ · 14 Sep 2026 20:00 UTC
Previous Close
$0.48
Day Range
$0.47$0.51
Year Range
$0.37$1.5
Market Cap
4.26M
AVG Volume
1.36M
Trailing/Forward PE
-0.52/-
PEG ratio
0.01
Dividend Yield
-
Next Earnings Date
2026-11-18
Primary Exchange
NASDAQUS
Revenue (USD)
02.5M5M7.5M10M2016201720182019202020212022202320242025
EVGN Revenue (USD) by year
PeriodRevenue (USD)
20253.95M
20248.15M
20235.64M
20221.68M
2021930K
20201.04M
2019753K
20181.75M
20173.38M
20166.54M
Net Income (USD)
-30M-20M-10M02016201720182019202020212022202320242025
EVGN Net Income (USD) by year
PeriodNet Income (USD)
2025-8.48M
2024-16.48M
2023-23.88M
2022-26.64M
2021-27.79M
2020-23.37M
2019-18.11M
2018-20.76M
2017-20.84M
2016-19.59M
Operating Income (USD)
-40M-30M-20M-10M02016201720182019202020212022202320242025
EVGN Operating Income (USD) by year
PeriodOperating Income (USD)
2025-15.13M
2024-19.2M
2023-26.51M
2022-26.94M
2021-30.95M
2020-24.81M
2019-21.17M
2018-19.99M
2017-21.95M
2016-21.09M
EBITDA (USD)
-30M-20M-10M02016201720182019202020212022202320242025
EVGN EBITDA (USD) by year
PeriodEBITDA (USD)
2025-13.01M
2024-13.32M
2023-23.26M
2022-27.01M
2021-27.88M
2020-23.21M
2019-16.02M
2018-17.97M
2017-19.8M
2016-18.81M
Cash Flows (USD)
-30M-20M-10M02016201720182019202020212022202320242025
EVGN Cash Flows (USD) by year
PeriodCash Flows (USD)
2025-14.14M
2024-20.33M
2023-22.09M
2022-24.85M
2021-25.56M
2020-20.2M
2019-18.26M
2018-15.8M
2017-16.52M
2016-12.5M
EPS (USD)
-6-4-202016201720182019202020212022202320242025
EVGN EPS (USD) by year
PeriodEPS (USD)
2025-1.17
2024-3.07
2023-5.17
2022-0.69
2021-0.69
2020-0.82
2019-0.7
2018-0.82
2017-0.81
2016-0.77
Expenses (USD)
010M20M30M40MR&DSG&ACapex2016201720182019202020212022202320242025
EVGN Expenses (USD) by year
PeriodExpenses (USD)
202515M
202425.01M
202331.24M
202232.38M
202131.84M
202025.96M
201922.48M
201820.66M
201723.07M
201622.8M
Cash & Debt (USD)
025M50M75M100MCashLong Term DebtShort Term Debt2016201720182019202020212022202320242025
EVGN Cash & Debt (USD) by year
PeriodCash & Debt (USD)
202512.96M
202415.31M
202331.06M
202235.35M
202153.87M
202048.23M
201946.88M
201854.47M
201771.75M
201688.11M
Debt ratios
00.20.40.60.820182019202020212022202320242025
EVGN Debt ratios by year
PeriodDebt ratios
20250.14
20240.03
20230.19
20220.25
20210.6
20200.59
20190.6
20180.76
Margins
-20%0%20%40%60%80%2016201720182019202020212022202320242025
EVGN Margins by year
PeriodMargins
2025-5.99%
202470.01%
202370%
202245.73%
202117.53%
202044.81%
201955.64%
201816.89%
201715.85%
201613.78%
Return on Capital
-150%-100%-50%0%2016201720182019202020212022202320242025
EVGN Return on Capital by year
PeriodReturn on Capital
2025-70.85%
2024-111.1%
2023-83.25%
2022-76.57%
2021-43.82%
2020-41.09%
2019-30.08%
2018-41.26%
2017-30.04%
2016-22.44%
Shares Outstanding
020M40M60M2016201720182019202020212022202320242025
EVGN Shares Outstanding by year
PeriodShares Outstanding
20258.72M
20246.8M
20235.06M
202241.23M
202141.18M
202034.15M
201925.75M
201825.75M
201725.93M
201625.55M
Book Value Per Share (USD)
02462016201720182019202020212022202320242025
EVGN Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
20251.37
20242.18
20235.67
20220.84
20211.54
20201.67
20192.34
20181.95
20172.68
20163.42
Total Assets (USD)
025M50M75M100M2016201720182019202020212022202320242025
EVGN Total Assets (USD) by year
PeriodTotal Assets (USD)
202520.05M
202439.86M
202351.1M
202256.13M
202176.3M
202071.92M
201971.36M
201858.69M
201777.6M
201695.99M
Employee Count
0501001502002016201720182019202020212022202320242025
EVGN Employee Count by year
PeriodEmployee Count
202552
2024117
2023142
2022137
2021141
2020131
2019143
2018150
2017165
2016185
Free Cash Flow Yield
-350%-300%-250%-200%-150%med -219.51%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
EVGN Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-191.57%
Sep 26-197.44%
Sep 26-176.22%
Aug 26-172.47%
Aug 26-168.51%
Aug 26-201.48%
Aug 26-201.71%
Jul 26-257%
Jul 26-223.13%
Jul 26-192.45%
Jul 26-236.42%
Jul 26-281.71%
Jun 26-311.26%
Jun 26-230.53%
Jun 26-207.31%
Jun 26-195.56%
May 26-171.7%
May 26-172.93%
May 26-221.38%
May 26-215.71%
May 26-211.68%
Apr 26-205.77%
Apr 26-202.56%
Apr 26-200.03%
Apr 26-206.87%
Mar 26-198.1%
Mar 26-191.66%
Mar 26-203.34%
Mar 26-211.21%
Feb 26-221.84%
Feb 26-237.27%
Feb 26-202.84%
Feb 26-180.3%
Jan 26-192.8%
Jan 26-183.71%
Jan 26-185.45%
Jan 26-175.43%
Jan 26-172.33%
Dec 25-189.06%
Dec 25-190.91%
Dec 25-180.3%
Dec 25-175.43%
Nov 25-183.71%
Nov 25-172.33%
Nov 25-208.47%
Nov 25-219.34%
Oct 25-200.19%
Oct 25-201.79%
Oct 25-201.79%
Oct 25-195.54%
Oct 25-219.34%
Sep 25-275.86%
Sep 25-266.51%
Sep 25-247.62%
Sep 25-262.07%
Aug 25-251.59%
Aug 25-240.06%
Aug 25-232.95%
Aug 25-259.9%
Aug 25-271.1%
Jul 25-240.06%
Jul 25-238.24%
Jul 25-229.55%
Jul 25-234.69%
Jun 25-241.91%
Jun 25-215.4%
Jun 25-227.89%
Jun 25-285.89%
May 25-288.52%
May 25-255.65%
May 25-228.33%
May 25-264.7%
May 25-253.48%
Apr 25-269.46%
Apr 25-308.36%
Apr 25-284.86%
Apr 25-251.35%
Mar 25-228.33%
Mar 25-256.29%
Mar 25-247.33%
Mar 25-238.97%
Feb 25-242.25%
Feb 25-249.07%
Feb 25-228.18%
Feb 25-242.25%
Jan 25-225.28%
Jan 25-213.06%
Jan 25-198.7%
Jan 25-225.28%
Jan 25-186.15%
Dec 24-214.35%
Dec 24-261.99%
Dec 24-258.16%
Dec 24-247.33%
Nov 24-219.68%
Nov 24-218.32%
Nov 24-227.22%
Nov 24-223.34%
Nov 24-175.48%
Oct 24-159.79%
Price to Sales
0246med 1.41Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
EVGN Price to Sales by year
PeriodPrice to Sales
Sep 264.62
Sep 264.48
Sep 265.02
Aug 265.13
Aug 265.25
Aug 263.17
Aug 263.17
Jul 262.49
Jul 262.87
Jul 263.32
Jul 262.7
Jul 262.27
Jun 262.05
Jun 262.77
Jun 263.08
Jun 263.27
May 263.72
May 263.7
May 261.61
May 261.66
May 261.69
Apr 261.74
Apr 261.77
Apr 261.79
Apr 261.73
Mar 261.8
Mar 261.87
Mar 261.76
Mar 261.69
Feb 261.46
Feb 261.36
Feb 261.59
Feb 261.79
Jan 261.68
Jan 261.76
Jan 261.74
Jan 261.84
Jan 261.88
Dec 251.71
Dec 251.69
Dec 251.79
Dec 251.84
Nov 251.76
Nov 251.88
Nov 251.31
Nov 251.24
Oct 251.36
Oct 251.35
Oct 251.35
Oct 251.4
Oct 251.24
Sep 251.21
Sep 251.25
Sep 251.35
Sep 251.27
Aug 251.33
Aug 251.39
Aug 251.43
Aug 251.29
Aug 251.23
Jul 251.39
Jul 251.4
Jul 251.46
Jul 251.42
Jun 251.38
Jun 251.55
Jun 251.47
Jun 251.17
May 251.16
May 250.98
May 251.09
May 250.94
May 250.98
Apr 250.93
Apr 250.81
Apr 250.88
Apr 250.99
Mar 251.09
Mar 251.13
Mar 251.17
Mar 251.21
Feb 251.19
Feb 251.16
Feb 251.27
Feb 251.19
Jan 251.28
Jan 251.36
Jan 251.45
Jan 251.28
Jan 251.55
Dec 241.35
Dec 241.1
Dec 241.12
Dec 241.17
Nov 241.31
Nov 241.32
Nov 240.96
Nov 240.98
Nov 241.25
Oct 241.37
Price to Book
0.40.60.811.2med 0.65Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
EVGN Price to Book by year
PeriodPrice to Book
Sep 261.05
Sep 261.02
Sep 261.14
Aug 261.16
Aug 261.19
Aug 260.73
Aug 260.73
Jul 260.57
Jul 260.66
Jul 260.77
Jul 260.62
Jul 260.52
Jun 260.47
Jun 260.64
Jun 260.71
Jun 260.75
May 260.86
May 260.85
May 260.53
May 260.55
May 260.56
Apr 260.57
Apr 260.58
Apr 260.59
Apr 260.57
Mar 260.6
Mar 260.62
Mar 260.58
Mar 260.56
Feb 260.44
Feb 260.41
Feb 260.49
Feb 260.55
Jan 260.51
Jan 260.54
Jan 260.53
Jan 260.56
Jan 260.57
Dec 250.52
Dec 250.52
Dec 250.55
Dec 250.56
Nov 250.54
Nov 250.57
Nov 250.71
Nov 250.67
Oct 250.74
Oct 250.73
Oct 250.73
Oct 250.75
Oct 250.67
Sep 250.63
Sep 250.65
Sep 250.7
Sep 250.66
Aug 250.69
Aug 250.72
Aug 250.74
Aug 250.66
Aug 250.64
Jul 250.72
Jul 250.72
Jul 250.75
Jul 250.73
Jun 250.71
Jun 250.8
Jun 250.76
Jun 250.6
May 250.6
May 250.54
May 250.6
May 250.52
May 250.54
Apr 250.51
Apr 250.44
Apr 250.48
Apr 250.55
Mar 250.6
Mar 250.65
Mar 250.68
Mar 250.7
Feb 250.69
Feb 250.67
Feb 250.74
Feb 250.69
Jan 250.74
Jan 250.79
Jan 250.84
Jan 250.74
Jan 250.9
Dec 240.78
Dec 240.64
Dec 240.65
Dec 240.68
Nov 240.76
Nov 240.77
Nov 240.44
Nov 240.45
Nov 240.57
Oct 240.63
Evogene Ltd.
EVGN
Stockpicker

Video analysis: EVGN

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: EVGN

EverGen to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

newsfilecorp.com · 14 Sep 2026

EverGen to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Vancouver, British Columbia--(Newsfile Corp. - September 14, 2026) - EverGen Infrastructure Corp. (TSXV: EVGN) (OTCQB: EVGIF) is pleased to announce its participation in the upcoming 3 rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Chase Edgelow, Co-founder & Chief Executive Office of EverGen, will participate as a Featured Company and will hold one-on-one meetings with interested investors and capital markets professionals.

Evogene Ltd. (NASDAQ:EVGN) Short Interest Down 77.2% in August

defenseworld.net · 11 Sep 2026

Evogene Ltd. (NASDAQ:EVGN) Short Interest Down 77.2% in August

Evogene Ltd. (NASDAQ: EVGN - Get Free Report) was the target of a large drop in short interest in August. As of August 31st, there was short interest totaling 53,001 shares, a drop of 77.2% from the August 15th total of 232,078 shares. Based on an average daily volume of 219,870 shares, the short-interest ratio is

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

prnewswire.com · 31 Aug 2026

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Company urges shareholders to evaluate the significant changes already implemented and vote FOR all Evogene nominees on September 4, 2026, Annual General Meeting REHOVOT, Israel, Aug. 31, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today responded to the latest communication from dissident shareholders L.I.A.

EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript

seekingalpha.com · 27 Aug 2026

EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript

EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript

EverGen Infrastructure Reports Q2 2026 Results

businesswire.com · 27 Aug 2026

EverGen Infrastructure Reports Q2 2026 Results

VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQB: EVGIF), today reported financial results as at and for Q2 2026. All amounts are in Canadian dollars and are presented in thousands of dollars unless otherwise stated and have been prepared in accordance with IFRS. Financial Highlights The following table presents EverGen's Consolidated Financial and Operating Summary:   Three months ended   June 30, 2026 June 30, 2025 $ C.

EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026

businesswire.com · 26 Aug 2026

EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN), is pleased to report the voting results from its Annual General Meeting of Shareholders (“AGM”) held on August 25, 2026. A total of 16,172,472 common shares were represented at the meeting, representing 62.43% of the Company's outstanding shares. The following is a summary of the proxy voting results for the AGM. 1. Election of Directors The following individuals were elected as.

EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

seekingalpha.com · 25 Aug 2026

EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

prnewswire.com · 25 Aug 2026

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

Recommendations Reinforce Confidence in Evogene's Strategic Plan and Long-Term Value Creation Strategy  Board Urges Shareholders to Vote FOR All Evogene Nominees, and to disregard the Pure Capital Nominees, at the September 4, 2026, Annual General Meeting REHOVOT, Israel, Aug. 25, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that leading independent proxy advisory firms Institutional Shareholder Services ("ISS") and Glass Lewis have recommended that Evogene shareholders vote "FOR" the Company slate of nominees in connection with the September 4, 2026 Annual General Meeting of Shareholders.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.